121 results about "Pain chronic" patented technology

The invention discloses a man-machine suitability evaluation method for a mattress, and relates to the field of human engineering health monitoring, and the method comprises the steps: screening testers according to a BMI grading standard, and collecting the height, weight, gender, age, sleep habit and chronic pain medical history basic data of the testers to obtain the BMI values of the testers; inputting the BMI value of the tester into the mattress hardness selection model to obtain the hardness range of the tested mattress, arranging a to-be-tested mattress with selected hardness in a constant-temperature and constant-humidity experimental environment, and enabling the tester to lie on the to-be-tested mattress in sequence at a standard supine position and a standard lateral position. According to the method, the spine stiffness demand curve is predicted in real time through the LSTM neural network, millisecond-level dynamic support adjustment is achieved, the response speed is remarkably increased compared with a traditional method, and spine compensatory bending in sleep can be prevented; and in combination with pressure-blood oxygen coupled IRI index calculation, microcirculation disturbance is accurately warned before tissue injury, and the problem of local ischemia is solved through partition adjustment.

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

According to the intelligent green light phototherapy glasses and the intelligent adaptation method thereof, a narrow-band green light LED light source with the central wavelength being 530 + / -5 nm is adopted, and individualized pain management is achieved in combination with heart rate variability, electrodermal response and pupil dynamic monitoring. A multi-source sensor and a micro control panel are arranged in the glasses, physiological data are collected in real time, the illumination intensity, frequency and irradiation mode are dynamically adjusted through an artificial intelligence algorithm, and a closed-loop phototherapy control system is constructed. The device supports Bluetooth / Wi-Fi connection, interacts with a mobile terminal APP, and realizes data recording, curative effect evaluation and remote monitoring. The system has multiple safety mechanisms such as constant-current driving, temperature feedback, over-illumination protection and posture detection, and long-term wearing safety is ensured. Through the regulation effect of green light on pain neural pathways, a safe, portable and intelligent chronic pain non-drug treatment means is provided under the condition that daily activities are not interfered, and high compliance and a remarkable analgesic effect are achieved.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

The invention provides a preparation method and application of graphene pain-relieving health-care paste, and the method comprises the following steps: mixing carrageenan with water to obtain a carrageenan solution, and carrying out ionization degradation on the carrageenan solution to obtain a carrageenan oligosaccharide solution; the preparation method comprises the following steps: stirring graphene oxide and a carrageenan oligosaccharide solution, cleaning to obtain a mixed solution, adding sodium alginate into the mixed solution to prepare a gel precursor, and adding an anhydrous calcium chloride solution and effective components into the gel precursor to obtain the pain-relieving gel, and drying the gel to obtain the health-care paste. The health-care ointment has the effects of promoting blood circulation, activating collaterals and inhibiting inflammation, and is suitable for various chronic pains such as rheumatic arthritis and lumbar muscle degeneration and acute pains such as traumatic injury and muscle strain; the composition is also suitable for auxiliary relieving of postoperative pain, and has safety and long-term effect. Due to the thermal conductivity of the graphene oxide in the health-care cream, local skin blood circulation can be accelerated, the permeation efficiency of the herbal extract is improved, and the medicine effect of the effective components is improved.

The present invention relates to compounds, compositions and methods for deinhibiting a RE1 silencing transcription factor (REST) target gene. In particular, disclosed is a peptide having the sequences TEDLEPPEPPLPKEN (SEQ ID NO: 1) and EDLEPPEPPLPK (SEQ ID NO: 15) or a reverse sequence (reverse inversion, RI) consisting of D-amino acids nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), for use in the inhibition of REST activity. The peptides can be used for treating, preventing or alleviating diseases such as traumatic brain injury, epilepsy, dementia, Huntington's disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer, diabetes and peripheral nerve injury.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

The invention relates to the field of guidance information recommendation, in particular to an AR-based chronic pain relieving guidance system and method, and the method comprises the steps: carrying out the continuous monitoring of each feedback monitoring parameter, and determining whether to carry out the optimization screening analysis or not according to a reference feedback evaluation index; determining execution association analysis or execution trend analysis according to the execution evaluation difference index and the execution evaluation trend index; when the correlation analysis is executed, determining parameters on which priority guidance information is selected according to the stage execution part parameters and the set evaluation difference index; when the execution trend analysis is carried out, determining whether optimization guidance information is determined or not according to the execution trend difference index; and when the optimal guidance information is determined, updating and replacing the pain relieving guidance scheme based on the determined optimal guidance information. According to the invention, the matching degree of the related medical record information of the patient is improved, so that the adaptation degree of the recommended guidance scheme is improved.

The present invention relates to an N-benzyl phthalimide derivative compound of formula I, a pharmaceutical composition comprising the same, a medicament, its use, combination, and methods for treating acute and chronic pain, primarily focusing on neuropathic disorders and syndromes associated with neuropathic pain.

The invention discloses a closed-loop analgesia method and system for regulating and controlling a secondary sensory cortex based on primary sensory cortex neural activity feedback. The system comprises a signal acquisition module used for acquiring neuron activity signals in the S1 region, a pain judgment module used for analyzing the signals and judging the pain state, a feedback control module used for generating stimulation control signals, and a stimulation execution module used for applying adjustable nerve regulation stimulation to the S2 region. According to the method, a specific pain nerve signal of S1 is monitored in real time and serves as a closed-loop feedback source, intervention on S2 is dynamically controlled, stimulation parameters are automatically started and optimized only when pain is detected, stimulation is automatically weakened or stopped after the pain fades away, and therefore self-adaptive, on-demand and accurate intelligent analgesia is achieved. According to the invention, accurate pain determination is realized by using a specific signal at the upstream of a pain pathway, personalized, efficient and low-energy-consumption intelligent analgesia is realized through closed-loop control, and a brand new solution is provided for chronic pain treatment.

The application discloses application of hen egg white lysozyme (HEL) in relieving chronic pain, and experiment results show that HEL significantly and selectively relieves inflammatory pain, neuropathic pain and static mechanical allodynia induced by chemotherapy pain. Meanwhile, experiments show that HEL causes the expression of a mechanical sensitivity ion channel TACAN in the PRKN / TACAN pathway on the cell membrane to be reduced by up-regulating the expression of PRKN protein of primary sensory neurons in the dorsal root ganglion, thereby significantly inhibiting static mechanical allodynia. The application firstly finds that HEL has the effect of relieving static mechanical allodynia and a deep mechanism, and the source of HEL is non-toxic and safe, and has potential application value in preparation of medicines for preventing, treating and relieving chronic pain, and has great clinical significance.

The present invention provides: a novel heteroaryl derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating AAK1 inhibition-related diseases, the composition comprising same as an active ingredient. The heteroaryl derivative compound according to the present invention exhibits excellent inhibitory activity against AAK1, and thus can be effectively used for preventing and treating AAK1 inhibition-related diseases such as acute pain and neuropathic pain.

Systems and techniques to determine programming of an implantable electrical neurostimulation device, through chronic pain treatment modeling that evaluates pain experience states and transitions for a patient. In an example, a system to determine programming of a neurostimulation device performs operations to: determine possible pathways to traverse pain experience states of a chronic pain condition, as the possible pathways provide respective paths among the states from a starting state to one or more intermediate states to a goal state; determine transition costs between the states used in the possible pathways, with respective pain experience states being associated with different pain management characteristics of neurostimulation therapy; identify a path of the possible pathways to reach the goal state, based on the transition costs and patient characteristics; and select programming parameters for the neurostimulation device, to provide neurostimulation therapy based on the identified path to achieve the goal state.

To provide compositions and methods for treating and preventing cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, and addiction.SOLUTION: Also provided are methods for the diagnosis and monitoring of cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, addiction, and other conditions such as convulsion or seizure. These compositions comprise fatty acid compounds and salts thereof which may be administered either alone, in combination with other medicaments, or as part of various treatment regimens. The provided compositions are effective for modulating markers, including, but not limited to, behavior associated with cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, opiate addiction, and other related conditions. Methods for administering the compositions are also provided.SELECTED DRAWING: Figure 1

This disclosure provides a method for treating a disease in a subject requiring treatment, such as chronic pain or IBS-D, the method of treating the disease by orally administering i) a therapeutically effective amount of buprenorphine dimer, or ii) a pharmaceutical composition comprising a therapeutically effective amount of buprenorphine dimer, wherein the buprenorphine dimer is represented by formula (I) or a pharmaceutically acceptable salt thereof. In particular, the administered buprenorphine dimer of formula (I) is in a neutral form. A method for producing a neutral form of buprenorphine dimer is also described.

A method and system for differentiating acute and chronic pain based on the functional state of specific neural circuits is proposed. This method utilizes in vivo two-photon / endoscopic calcium imaging and ex vivo brain slice patch-clamp techniques to longitudinally monitor the activity dynamics of neurons in the DRN and ZI brain regions during the acute and chronic phases of a neuropathic pain model. By extracting and analyzing calcium and electrophysiological signal parameter sets, distinguishing criteria are established: if the activity of 5-HTergic neurons in the DRN is specifically enhanced in the acute phase, the indication is acute pain; if the activity of GABAergic neurons in the ZI is specifically enhanced in the chronic phase, the indication is chronic pain. This invention achieves an objective and precise differentiation of the transition from acute to chronic pain at the level of specific neural circuits, providing a new strategy and tool for pain mechanism research and clinical diagnosis and treatment.

The invention relates to bromhexine or a salt thereof for treating acute or chronic pain in a patient. In particular, the invention relates to bromhexine or a salt thereof for use in treating nociceptive pain, neuropathic pain and or dysfunctional pain. The invention further relates to a topical pharmaceutical composition comprising bromhexine or a salt thereof and to a composition or a topical pharmaceutical composition comprising bromhexine or a salt thereof for treating acute or chronic pain.

The present disclosure provides a method of treating a disease (e.g., chronic pain or IBS-D) in a subject in need thereof by oral administration: i) a therapeutically effective amount of buprenorphine dimer; or ii) a pharmaceutical composition comprising a therapeutically effective amount of the buprenorphine dimer wherein the buprenorphine dimer is represented by Formula (I): or a pharmaceutically acceptable salt thereof, in particular, the administered buprenorphine dimer of Formula (I) is in a neutral form, methods of preparing the buprenorphine dimer in neutral form are also described.

The invention belongs to the field of polypeptides, and particularly relates to a TLR4 binding peptide and application thereof. The specific technical scheme is as follows: the nucleotide sequence of the polypeptide is edited as shown in SEQ ID NO: 1. The binding peptide containing 67 amino acids is screened out, is good in solubility, can be stably bound with TLR4, and is expected to become a new medicine for treating or relieving pain including chronic pain. The polypeptide can also be prepared into health care products, special medical foods and the like with the function of treating or relieving pain according to actual conditions.

The present invention provides use of lncRNA XR_595534.2 in the preparation of a medicine for the treatment or prevention of chronic pain. In the present invention, trigeminal neuralgia induced by chronic constriction injury of infraorbital nerve in rats is used as a pain model. A specifically and differentially highly expressed long-chain non-coding RNA gene lncRNA XR_595534.2 is screened in the model. An interfering RNA targeting lncRNA XR_595534.2 is provided for disease treatment. The present invention discovers for the first time that lncRNA XR_595534.2, which is specifically and differentially highly expressed in a pain model, has significantly reduced expression by stereotactic injection of an interfering RNA to relieve the pain behavior, and is useful in the preparation of a medicine for the treatment or prevention of trigeminal neuralgia, neuropathic pain, migraine and cancer pain where lncRNA-XR595534.2 is a target.

Embodiments described herein generally relate to methods and apparatus for adjusting and / or controlling body temperature and / or the flow of blood within blood vessels within a mammal. Embodiments of the present disclosure may further provide a therapeutic method for acute and preventive treatment of a migraine headache or other recurrent acute or chronic pain of a user, comprising: applying a vacuum to a portion of a body of a user and circulating warmed water over a surface of the portion of the body of the user, wherein applying the vacuum and circulating the warmed water is configured to overcome a vasoconstricted state of the portion of the body and manipulate blood flow to a head and / or distal appendages of the user.

Short pulse width spinal cord modulation for inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, modulation signal has pulse widths in the range of from about 10 microseconds to about 50 microseconds may be applied to the patient's spinal cord region to address chronic pain without using paresthesia or tingling to mask or cover the patient's sensation of pain. In other embodiments, modulation in accordance with similar parameters can be applied to other spinal or peripheral locations to address other indications.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The invention relates to medical and veterinary applications, in particular, as a means for effective control of acute and / or chronic pain, and can be used in emergency medicine for the treatment of acute and / or chronic pain, including the final stages of cancer. The claimed means is based on a compound for the prevention and / or treatment of acute or chronic pain in a subject, comprising an analgesic peptide having the amino acid sequence H-Tyr-D-Arg-Phe-Gly-NH2 or the amino acid sequence H-Tyr-D-Arg-Phe-Sar-OH. Also disclosed is a method of using the compound for the prevention and / or treatment of acute and / or chronic pain.

The present invention relates to therapeutic compounds, novel RNA interference (RNAi) agents that reduce the expression of a voltage gated sodium channel alpha subunit 10 (SCN10A) gene encoding a Nav 1.8 or a subunit of the Nav 1.8 sodium channel. Such RNAi agents reduce the level of the intact Nav 1.8 sodium channel and are useful in the treatment of diseases involving regulation of SCN10A expression and function, such as chronic pain.

The present disclosure relates to a tumor necrosis factor receptor 2 (TNFR2) agonist polypeptide comprising (i) a TNFR2 binding domain comprising three TNF homologous domains (THDs) that specifically bind to TNFR2; and (ii) an Fc domain. The present disclosure also relates to TNFR2 agonists for use in the treatment and / or prevention of e.g. Chronic pain or multiple sclerosis.

This disclosure relates to compounds of formula I (wherein X and R1-R4, n and m have the meanings set forth herein) and pharmaceutically acceptable salts thereof. Compounds of formula I exhibit GPR183 antagonist activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases for which GPR183 antagonists have been shown to be useful, such as chronic pain, e.g., osteoarthritis, chronic low back pain, neuropathic pain, and immune system disorders, e.g., inflammatory bowel diseases such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, e.g., asthma, and psoriasis. TIFF2026522963000085.tif2570

The invention belongs to the technical field of biological appliances for medical research, and particularly relates to a urinary surgery CP / CPPS model and a modeling method thereof. The modeling method comprises the following steps: (1) preparing prostate homogenate: taking rats of 4 months old, stripping prostate tissues under a sterile condition after the rats are killed, and grinding or homogenizing to prepare an injection suspension; (2) preparing a vaccine intraperitoneal injection: dissolving the inactivated vaccine freeze-dried powder into aluminum hydroxide gel normal saline to prepare the vaccine intraperitoneal injection; (3) injection of molding liquid: after anesthetizing the mouse, subcutaneously injecting prostate homogenate suspension, and intraperitoneally injecting vaccine intraperitoneal injection; and repeating the injection step until the mouse CP / CPPS model is formed. The modeling material disclosed by the invention can be conveniently purchased, the modeling material has common phenotypes of emotional abnormalities such as pain sensitization, anxiety, depression and the like of chronic pain after being molded, the phenotypes after modeling can be maintained for at least 90 days and can exceed half a year at most, the success rate of single-batch modeling is high, and the case fatality rate is low.

The Intelligent Pain Management Patch System (IPMPS) is a wearable medical device designed to deliver personalized and continuous pain relief for palliative care patients. The system integrates advanced sensor technology, a smart drug delivery system, and AI-driven pain assessment. The patch continuously monitors patient physiological parameters, assesses pain levels in real-time using AI, and administers precise doses of analgesic medication. The system includes a user interface for healthcare providers and patients, facilitating remote monitoring and adjustments. The IPMPS offers a non-invasive, personalized approach to managing chronic pain, reducing the need for oral medications and minimizing side effects.